This is a fixed-combination formulation containing sildenafil and tadalafil, both PDE5 inhibitors, alongside oxytocin, a neuroendocrine hormone. The combination is studied for its role in vascular and oxytocin signaling and the associated neuroendocrine pathways.

This combination formulation is used in controlled laboratory workflows and investigative settings examining PDE5 and oxytocin receptor activity, vascular signaling, and behavior-related mechanisms. It is applied in structured research models characterizing compound activity and downstream pathway interactions.

The combination supports analytical studies and cell-based models involving PDE5 inhibition, vascular signaling, oxytocin-mediated pathways, arousal-related mechanisms, and neuroendocrine cross-talk. It is relevant for pathway characterization and assay development focused on vascular, behavioral, and hormonal mechanisms within controlled study frameworks.

This combination is suited for researchers and investigators studying PDE5 vascular signaling alongside oxytocin receptor mechanisms within controlled study frameworks.